Abstract:Hypoxia inducible factor (HIF) is a heterodimeric transcription factor composed of an oxygen-regulated α subunit and a constitutively expressed β subunit that serves as the master regulator of the cellular response to low oxygen concentrations. The HIF transcription factor senses and responds to hypoxia by significantly altering transcription and reprogramming cells to enable adaptation to a hypoxic microenvironment. Given the central role played by HIF in the survival and growth of tumors in...

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve The paper aims to develop cyclic peptide inhibitors that can suppress hypoxia-inducible factors (HIF) 1 and 2 by interfering with the protein-protein interactions (PPI) between HIF-1α and HIF-2α with HIF-1β, thereby disrupting the hypoxia response signaling pathway in cancer cells. ### Background and Significance Hypoxia-inducible factors (HIF) are heterodimeric transcription factors composed of an oxygen-regulated α subunit and a constitutively expressed β subunit. HIF senses and responds to hypoxic conditions, significantly altering transcription and reprogramming cells to adapt to the hypoxic microenvironment. HIF plays a central role in tumor survival and growth, thus inhibiting HIF transcription factors is considered a potential approach for treating various cancers. ### Main Research Content 1. **Identification and Optimization of Cyclic Peptide Inhibitors**: - The research team screened a library of 3.2 million cyclic hexapeptides to identify those capable of interfering with HIF-1α/HIF-1β and HIF-2α/HIF-1β PPI. - Through a series of experiments, including molecular dynamics simulations, molecular docking, and binding affinity measurements, several cyclic peptide candidates with high affinity were identified. 2. **Identification of Active Pharmacophores**: - Alanine scanning mutagenesis experiments identified the key pharmacophore in the cyclic peptide cyclo-CRLIIF as the IFC tripeptide. - Further optimization of this pharmacophore, by introducing non-natural amino acids, particularly 4-iodophenylalanine, significantly improved the binding affinity of the cyclic peptide. 3. **Evaluation of Intracellular Activity**: - The intracellular activity of the optimized cyclic peptide cyclo-CRLII(4-iodo)F was evaluated in various cancer cell lines. - Results showed that this cyclic peptide effectively reduced HIF-driven gene expression under hypoxic conditions, such as CAIX and VEGF, and exhibited consistent inhibitory effects across multiple cell lines. ### Conclusion The study successfully developed a series of cyclic peptide inhibitors that can simultaneously inhibit HIF-1 and HIF-2 by interfering with the PPI between HIF-α and HIF-1β, effectively disrupting the hypoxia response signaling pathway. This discovery provides an important foundation for developing novel therapeutic strategies against various cancers.

Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Identification of Cathepsin B As a Novel Target of Hypoxia-Inducible Factor-1-alpha in HepG2 Cells.

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation

Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway

The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Using β-Lactamase and NanoLuc Luciferase Reporter Gene Assays to Identify Inhibitors of the HIF-1 Signaling Pathway

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators

Targeting HIF-1 for cancer therapy

Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells

Hypoxia-inducible Factor-1 in Tumour Angiogenesis

Hypoxia-inducible factor-1 in tumour angiogenesis.

HIF-1-Regulated Glucose Metabolism: A Key to Apoptosis Resistance?

HIF-1α pathway: role, regulation and intervention for cancer therapy

Identification of Chemical Compounds That Induce HIF-1alpha Activity.

Targeted Genes and Interacting Proteins of Hypoxia Inducible Factor-1.